Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (BEIGF) Equity Average (2016 - 2025)

Historic Equity Average for BeOne Medicines (BEIGF) over the last 10 years, with Q3 2025 value amounting to $3.9 billion.

  • BeOne Medicines' Equity Average rose 1613.38% to $3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year increase of 1613.38%. This contributed to the annual value of $3.4 billion for FY2024, which is 1327.07% down from last year.
  • BeOne Medicines' Equity Average amounted to $3.9 billion in Q3 2025, which was up 1613.38% from $3.6 billion recorded in Q2 2025.
  • BeOne Medicines' Equity Average's 5-year high stood at $6.0 billion during Q1 2022, with a 5-year trough of $3.4 billion in Q2 2024.
  • In the last 5 years, BeOne Medicines' Equity Average had a median value of $3.8 billion in 2021 and averaged $4.1 billion.
  • Per our database at Business Quant, BeOne Medicines' Equity Average soared by 10688.51% in 2021 and then plummeted by 2827.02% in 2023.
  • BeOne Medicines' Equity Average (Quarter) stood at $4.7 billion in 2021, then fell by 4.75% to $4.5 billion in 2022, then dropped by 19.23% to $3.7 billion in 2023, then decreased by 7.29% to $3.4 billion in 2024, then rose by 16.72% to $3.9 billion in 2025.
  • Its Equity Average was $3.9 billion in Q3 2025, compared to $3.6 billion in Q2 2025 and $3.4 billion in Q1 2025.